FY2027 EPS Estimate for Oncolytics Biotech Lifted by Analyst

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Equities research analysts at HC Wainwright boosted their FY2027 earnings estimates for Oncolytics Biotech in a research report issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.08) for the year, up from their previous estimate of ($0.09). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2028 earnings at $0.39 EPS.

Several other equities research analysts have also recently issued reports on ONCY. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th. Maxim Group cut their price objective on shares of Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday. Finally, Royal Bank of Canada lowered their target price on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Monday. Three investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $4.00.

Oncolytics Biotech Trading Down 1.1 %

Oncolytics Biotech stock opened at $0.62 on Thursday. Oncolytics Biotech has a 12-month low of $0.58 and a 12-month high of $1.53. The stock has a market cap of $53.27 million, a P/E ratio of -2.31 and a beta of 1.18. The company has a 50-day moving average price of $0.77 and a 200 day moving average price of $0.92.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ONCY. Virtu Financial LLC purchased a new position in Oncolytics Biotech during the fourth quarter worth about $90,000. National Bank of Canada FI boosted its stake in Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after buying an additional 42,955 shares during the period. Vantage Point Financial LLC purchased a new position in shares of Oncolytics Biotech in the fourth quarter valued at approximately $27,000. International Assets Investment Management LLC boosted its stake in shares of Oncolytics Biotech by 15.0% in the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after purchasing an additional 26,069 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Oncolytics Biotech by 59.6% in the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after purchasing an additional 24,997 shares during the period. Hedge funds and other institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.